GU Cancers 2022 | SWOG S1314: overall survival results

Thomas W. Flaig, MD, University of Colorado Anschutz Medical Campus, Aurora, Colorado, outlines the Phase II SWOG S1314 (NCT02177695) exploring coexpression extrapolation (COXEN) for the prediction of response to chemotherapy in patients with bladder cancer. COXEN is an algorithm developed by Theodorescu and colleagues that performs as a predictive biomarker to drug sensitivity of cancer cells. It was found that the COXEN GC score may be prognostic of survival in those receiving platinum-based neoadjuvant treatment. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.